CiteFacts · FDA Drug Shortages · FDA source
Dexamethasone Sodium Phosphate Injection
Status
FDA currently lists this ingredient in shortage.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| Eugia US LLC | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25) | Available | 08/06/2026 |
| Fresenius Kabi USA, LLC | Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10) | Limited Availability | 08/04/2026 |
| Fresenius Kabi USA, LLC | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10) | Limited Availability | 08/04/2026 |
| Fresenius Kabi USA, LLC | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10) | Available | 08/04/2026 |
| Hikma Pharmaceuticals USA, Inc. | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25) | Available | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25) | Available | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25) | Available | 08/13/2026 |
| Mylan Institutional, a Viatris Company | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10) | Available | 08/20/2026 |
| Mylan Institutional, a Viatris Company | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30) | Available | 08/20/2026 |
| Mylan Institutional, a Viatris Company | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54) | Available | 08/20/2026 |
| Mylan Institutional, a Viatris Company | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12) | Available | 08/20/2026 |
| Somerset Therapeutics, LLC | Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25) | Available | 07/20/2026 |
| Somerset Therapeutics, LLC | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10) | Available | 07/20/2026 |
Source facts
Grouped generic ingredient: Dexamethasone Sodium Phosphate Injection · 19 package records · Latest FDA row update: 08/20/2026
Therapeutic categories: Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology
Dosage forms: Injection
Routes: INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRAVENOUS, SOFT TISSUE
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.